ZEALAND PHARMA A/S shares fell 13% on Thursday after trial data showed nearly one in five patients quit late-stage survodutide trials due to gastrointestinal side effects. It is the second time this year that dropout concerns have hit the Denmark-based drugmaker. The obesity drug, developed in partnership with Boehringer Ingelheim, faces scrutiny over tolerability.

Trial Design Limits Dosing Flexibility